Carbylan Therapeutics revives IPO plans, chops target number

Carbylan Therapeutics refiled its IPO plans on Monday, cutting the amount it is seeking by about 26 percent less than when it postponed plans to go public two months ago...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.